Phaseline

Targets › IL17F

IL17F (Interleukin-17F): drug programs, companies and trials

2 programs from 2 companies in 11 trials: 8 Phase 3, 2 Phase 1, 1 Phase 2; Immunology, Infectious disease; next expected readout Dec 2026.

Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. IL17A-IL17F signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter through SEFIR domains. (UniProt, Q96PD4)

Open in Phaseline: the race on IL17F, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UCB Biopharma SRLBimekizumab
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis …Dec 2026
MoonLake ImmunotherapeuticsM-1095
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Arthritis, PsoriaticJan 2027

Conditions

Moderate to Severe Plaque Psoriasis (3) Hidradenitis Suppurativa (2) Arthritis, Psoriatic (2) Palmoplantar Pustulosis (1) Enthesitis-related Arthritis (1) Psoriatic Arthritis (1) Psoriasis (1)

Modalities

antibody (1), mixed (1)

Companies

MoonLake Immunotherapeutics (1) UCB Biopharma SRL (1)

Related targets

IL17A (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.